and Pharmaceutical Sciences, University of Manchester, UK; tel +44 (0) HepaRG cells was on average within two-fold of in vivo CLint (using the Well-stirred liver model), but average fold error was clearance dependent with greater underprediction (up to at least 5-fold) for the more highly cleared drugs. Recent reporting of this phenomenon in human hepatocytes was therefore confirmed with the hepatocytes used in this study and hence the HepaRG cell system appears to share an apparently general tendency of clearance limited CLint in cell models. This study shows the cryopreserved HepaRG cell system to be quantitatively comparable with human hepatocytes for prediction of clearance of drug cytochrome P450 substrates and to represent a promising alternative in vitro tool.
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INTRODUCTION
Clearance is of pivotal importance in drug discovery and hence much effort to predict human clearance is focussed on the early stages of drug discovery. Demand has increased as technology for screening has developed. However, despite technological advances in human liver derived in vitro systems over the last two decades, and improvements in understanding prediction methodology, accurate prediction of intrinsic clearance (CLint) in vivo remains elusive.
Currently, the isolated human hepatocyte represents the most versatile human hepatic in vitro system in standard use and an improvement over the established hepatic microsomes standard, due to a more complete set of uptake, metabolism and elimination routes. However, prediction of clearance from hepatocytes, as with hepatic microsomes, is imprecise with bias towards underprediction (Hallifax et al., 2010) . A major source of uncertainty in prediction of clearance is the phenotypical expression of human cytochrome P450 and (by implication) transporters; in addition, the impact on these activities by liver processing and storage procedures may be a trend towards loss of activity (Hallifax and Houston, 2009) . Introducing an extrapolation factor to compensate for the average bias (underprediction) in prediction of clearance from hepatocytes has been suggested (Stringer et al., 2008; Hallifax et al., 2010 ) but this will not improve the precision of predictions. However, the reliance on an in vitro system obtained directly from human donors, with the additional difficulty of limited supply, may be challenged by cell line systems which have been developed in recent years.
A promising potential alternative to primary hepatocytes is the HepaRG cell system which has been derived from human immortalized hepatoma cells. HepaRG cells retain most liver functions, including cytochrome P450 drug metabolising enzymes (Guillouzo et al., 2007) . These cells, when plated at low density with medium This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 13, 2011 as DOI: 10.1124 at ASPET Journals on June 1, 2017 dmd.aspetjournals.org Downloaded from DMD #42309 6 containing DMSO, differentiate into two cell types, resembling either adult primary hepatocytes (with bile canaliculi) or biliary epithelial cells (Parent et al., 2004) and are able to perform many specific liver functions and respond to prototypical drug metabolism inducers. Moreover, modulation of the concentration of DMSO during the differentiation process can result in expression of cytochrome P450 and transporters at levels similar to or greater than primary human hepatocytes in culture (Aninat et al., 2006; Lübberstedt et al., 2011) . Since becoming available, HepaRG cells have been used successfully for assessment of cytochrome P450 induction (McGinnity et al., 2009; Anthérieu et al., 2010) and toxicology studies (Dumont et al., 2010; Lübberstedt et al., 2011; McGill et al., 2011) and appear to have the potential for further understanding of the interplay between drug metabolism, cell metabolism and liver function in preclinical toxicological studies for either known drugs and new chemical entities. Kanebratt and Andersson (2008) have demonstrated activities of several major drug metabolizing cytochrome P450s in cultured HepaRG cells which were of a similar magnitude to that in primary hepatocytes. This indication of the quantitative performance of the HepaRG system has been encouraging for the further development of a readily available in vitro model suitable for high-throughput use. Recently, Biopredic International have developed cryopreservation of the HepaRG cell system which appears to offer convenience to match that of cryopreserved primary hepatocytes, such as being more amenable to automated assay.
The aims of this study were twofold. First, we present an evaluation of the cryopreserved HepaRG cell system for prediction of hepatic clearance using standard high-throughput methodology. A set of 26 drug substrates was selected on the basis of availability of clinical pharmacokinetic data over a wide range of clearances together with a range of cytochrome P450-mediated pathways, This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . Intrinsic clearance (CLint) was determined by substrate depletion and compared to values obtained in a parallel study using pooled cryopreserved human hepatocytes. CLint was also compared to in vivo (clinical) CLint and prediction accuracy assessed. Secondly, the human hepatocyte data collected was used as a consistent dataset to explore the validity of previous hepatocyte studies of similar size (Foster et al., 2011) to investigate trends in prediction occurring and utility for in vivo prediction.
This article has not been copyedited and formatted. The final version may differ from this version. International (Rennes, France). HBSS without phenol red (10x) and HEPES buffer solution 1 were purchased from Gibco-Invitrogen (Carlsbad, CA); Williams' Medium E (WME) and all other chemicals not specified above were purchased from SigmaAldrich (St. Louis, MO).
HepaRG cell incubations. HepaRG cells stored in liquid nitrogen were thawed
according to the instructions from the supplier and resuspended in WME (serum and phenol free) at 37°C in a fresh tube. In viability counting, all cells appeared spheroid in shape and no morphological difference (hepatocyte v. biliary cell) was detected; therefore, calculation of viability and CL int , was based on the total number of cells.
The substrates (Table 1) were prepared as solutions in aqueous DMSO (10 mM), diluted first to 2 mM in acetonitrile/water (50/50) and then diluted to 2 µM in WME.
Each incubation volume (125 µl) was prepared by mixing an equal amount of cell suspension and compound dilution in a 96 well plate to obtain the final conditions of 0.05 % of total organic solvent, 1 µM compound, and 0.25 x 10 6 cells/ml. The concentration of cell in the incubation was selected to match that determined for hepatocytes (below). Incubation plates were maintained at 37°C and shaken on a Thermoshake TM (INHECO, Munich, Germany Hepatocyte incubations. Hepatocytes stored in liquid nitrogen were rapidly thawed in a shaking water bath at 37°C and recovered after centrifugation (75 g; room temperature) in CHPTM medium. The cells were resuspended in WME (serum and phenol free) at 37°C in a fresh tube. Viability was checked to be above 70 % and cell concentration adjusted to obtain 0.5 x 10 6 cells/ml. The same procedure as for hepaRG cells was then followed using the same 26 substrates plus a further 15
substrates (Table 1) selected from a database of predictions of CLint (Hallifax et al., 2010) ; these additional substrates were employed to potentially improve comparison with previously reported data from this system. Prior to these experiments, a trial incubation with prototypical cytochrome P450 probes (nifedipine, diclofenac, testosterone) and verapamil was conducted to evaluate depletion rate linearity with cell concentration from 0.1 to 2 x 10 6 cells/ml; lower intrinsic clearance was obtained at 1 and 2 x 10 6 cells/ml and so the concentration of 0.25 x 10 6 cells/ml was selected for incubations. Each incubation was performed in duplicate (replicate data were accepted within 10 % of each other). 40°C and eluted within 1.8 min by a binary gradient from 0 % at 0.3 min to 100 % at 
Where: C t and C 0 are substrate concentration in the incubation medium at time t and initially, respectively; k is the rate constant. Fraction unbound in the incubation was calculated according to Kilford et al. (2008) :
Where: log P/D is log P for neutral and positively charged compounds and log D for acidic compounds.
Calculation of CL int observed in vivo.
The intrinsic clearance observed in vivo (CL int,u,Obs ) was calculated using the Well-stirred (WS) liver physiological model (Equation 4). This choice of liver model was based on adequacy for the objectives of this study when considering the marginal difference that we found using the most common alternative, the parallel tube model, in agreement with expectation from previous observations (Ito and Houston, 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Where: CL h is hepatic clearance, f ub is fraction unbound in blood and Q h is hepatic blood flow of 20.7 ml/min/kg body weight (Davis and Morris, 1993).
Fraction unbound in blood (f ub ) was derived from the literature (Stringer et al., 2008; Hallifax et al., 2010) .
Calculation of precision and accuracy. The accuracy of a set of predictions of
CLint for different drugs, given as the ratio of in vitro CLint (predicted) and in vivo CLint (observed) was assessed using the average fold error (AFE; geometric mean error) determined by Equation 5 (Obach, 1997):
Fold underprediction = 1/AFE
The corresponding precision of the prediction sets was assessed using the root mean squared error (RMSE) determined using Equation 6 (Sheiner and Beal, 1981):
Relation of predicted in vitro CL int and in vivo
To provide a correlation of in vitro CLint with in vivo CLint, where lack of proportionality was observed, the following log linear function was fitted by least squares regression using Microsoft Excel:
This article has not been copyedited and formatted. The final version may differ from this version. Table 2 . CL int,u ranged between 0.5 and 2100 ml/min/kg for HepaRG cells and 2.6 and 1900 ml/min/kg for hepatocytes. Although there were differences between the systems on an individual drug basis (notably tolbutamidesee Discussion), a direct correlation of CL int,u between the systems was apparent over the range of CL int,u investigated ( Figure 1 ). This correlation showed that the average ratio between the systems was close to unity, indicating a quantitative similarity in drug depletion between the HepaRG cells and the hepatocytes over the entire range of CLint examined.
Prediction of in vivo CLint. Intrinsic clearances for HepaRG cells and hepatocytes
together with CL int,u calculated from in vivo are shown in Table 2 The accuracy of prediction of CLint was assessed by AFE between in vitro and in vivo. On average, HepaRG cells and hepatocytes both underpredicted in vivo CLint but to a similar extent: 1.9-and 1.8-fold, respectively, confirming the direct correlation between the systems (Table 3 ). Precision among predictions was similar between the systems, with RMSE of 5531 for HepaRG cells and 4546 for hepatocytes (Table 3) .
This article has not been copyedited and formatted. The final version may differ from this version. When drugs were subdivided into groups according to level of CLint (by order of magnitude range), there was a clear trend towards decreasing prediction ratio with increasing CLint (Table 3) : compounds with CL int,u,Obs lower than 10 ml/min/kg were generally overpredicted in both systems by a factor of at least 3 (45.9-and 3.0-fold in HepaRG cells and hepatocytes, respectively); compounds with CL int,u,Obs between 10 and 100 ml/min/kg were up to 2-fold underpredicted (1.4-and 2.1-fold in HepaRG cells and hepatocytes, respectively); compounds with CL int,u,Obs between 100 and 1000 ml/min/kg were more underpredicted (3.1-and 6.7-fold in HepaRG cells and hepatocytes, respectively) as were compounds with CL int,u,Obs greater than 1000 ml/min/kg (5.9-and 5.0-fold in HepaRG cells and hepatocytes, respectively). The trend in bias indicated by individual fold errors is illustrated in Figure 3 .
Segregation of drugs according to the major cytochrome P450 (CYP) or Phase II clearance pathway showed that for the all major routes except CYP2D6, underprediction was within 2-fold (Table 4) ; for those drugs for which CYP2D6 is a major pathway, underprediction was only marginally greater, at 3-and 2-fold for HepaRG and hepatocytes, respectively (Table 4) CLint in HepaRG cells was on average equal to CLint in the hepatocytes and directly proportional over the entire range of CLint (1-2000 ml/min/kg), indicating that the HepaRG cell system is quantitatively very similar, in terms of prediction of hepatic clearance, to cryopreserved hepatocytes; there was no clearance dependent bias between the systems as has been reported between human liver microsomes and hepatocytes, in a recent database analysis of predictions (Hallifax et al., 2010) .
Although the ratio of CLint between the systems varied depending on drug, segregation of predictions according to primary metabolic pathway showed no evidence that this variation was associated with any specific cytochrome P450. One previous report that characterized HepaRG based on prototypical probe substrate found a lower level of metabolism of 7-ethoxycoumarin and dextromethorphan demethylase (Kanebratt and Andersson, 2008) whereas in another report, CYP1A
and 2D6 activities were considered similar to hepatocyte preparation (Turpeinen et al., 2009; Luberstedt et al., 2010) . In the present study, although this pathway analysis was partly obscured by the incidence of multiple cytochrome P450 pathways, it may be encouraging that there were no major deviations in CLint between the systems with regard to any prior concerns about potentially unrepresentative expression of cytochrome P450 in the HepaRG system (with the exception of tolbutamide: a low CLint in hepatocytes relative to microsomes indicated a more specific cause, such as uptake transport, as good CYP2C9 expression was indicated by warfarin and diclofenac - Brown et al., 2007) .
When CLint in the HepaRG system (scaled to whole body) was compared with in vivo CLint (calculated using the well-stirred liver model), the average ratio indicated an underprediction bias (by AFE) of just less than two-fold. This level of bias may be considered minor with respect to the historical average prediction bias from hepatocytes of about five-fold (Hallifax et al., 2010) .
Average prediction of CLint from
This article has not been copyedited and formatted. The final version may differ from this version. the hepatocytes in this study was also within two-fold, indicating above-average (historical) metabolic rates within the sample of hepatocytes used.
It has recently been shown that the bias in prediction of CLint from hepatocytes is clearance dependent, with greater bias observed in vitro with increasing level of CLint (Hallifax et al., 2010; Foster et al., 2011) . Segregation of in vitro/in vivo ratio of CLint in the present study showed that bias in the HepaRG system was also clearance dependent, confirming that use of average bias can be misleading and that substantial underprediction of CLint can occur for highly cleared drugs. This was supported by a similar clearance dependency in bias from the hepatocytes in the present study, which appears to substantiate this effect as a more general in vitro cellular phenomenon (supported by the additional substrates used with hepatocytes in the present study, n = 41, and the similar correlation slopes in this and previous studies, as above). Only marginal differences in predictions of CLint arise between use of the Well-stirred and Parallel Tube liver models and clearance dependency in prediction bias has been shown to be independent of liver model (Hallifax et al., 2010) . Currently, it can only be speculated as to the cause of this rate limitation. Huang et al. (2010) demonstrated that underprediction of a set of in-house compounds by hepatocytes was due to biliary efflux in vivo, a phenomenon which is not accounted for in vitro systems; however, in the present study, this is unlikely to apply because substrates of transporters (particularly Pgp) were avoided. More appropriate to the drugs used in this study, Foster et al. (2011) speculated that clearance dependency in prediction of CLint may be due to a capacity limitation, such as cofactor exhaustion or, alternatively, permeation rate limitation in vitro.
The sets of predictions of CLint from the two in vitro systems in this study were characterised with a similar level of imprecision, which reinforces a broad quantitative similarity in the performance of the novel HepaRG system with the alternative cryopreserved hepatocyte system, although this imprecision was greater than that reported for a larger database of published predictions (Hallifax et al., 2010) . Overall, the similarity in performance with hepatocytes that this study has demonstrated is reassuring with regard to the quantitative application of HepaRG cells, providing that precautions for the clearance dependent bias, can be applied.
Similarity with hepatocytes indicates that a simple correction could be applied, as has been suggested for hepatocytes (Foster et al., 2011) , to avoid critical misidentification of very highly cleared compounds at the drug candidate screening stage; in the case of the HepaRG system, this might simply require adjustment of the intercept of the suggested empirical correction (to reflect lower average bias).
Because of the nature of its production, the HepaRG system appears to represent a more consistent in vitro model with regard to reproducible expression of cytochrome P450s and possibly other metabolic enzymes which, considering the variability in cytochrome P450 activity that can arise in terms of phenotypic expression with current in vitro systems, may be a key benefit of this novel system.
In conclusion, this study has shown the potential of the cryopreserved HepaRG cell system as a quantitative in vitro model for prediction of intrinsic clearance which may provide a standardised alternative to the currently used liver donor-derived hepatocyte. Also, the clearance dependent in vivo prediction of human hepatocytes is confirmed.
